✦ LIBER ✦

How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?

✍ Scribed by Chaparro, María; Gisbert, Javier P

Book ID: 127148191
Publisher: Informa plc
Year: 2014
Tongue: English
Weight: 290 KB
Volume: 13
Category: Article
ISSN: 1474-0338
DOI: 10.1517/14740338.2014.959489

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy of inflammatory bowel diseases i

Therapy of inflammatory bowel diseases in pregnancy and lactation

✍ Cassina, Matteo; Fabris, Luca; Okolicsanyi, Lajos; Gervasi, Maria Teresa; Memmo, 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 334 KB

Sa2034 Early Discontinuation of Inflixim

Sa2034 Early Discontinuation of Infliximab During Pregnancy Reduces Neonatal Exposure to Infliximab and is Safe for the Inflammatory Bowel Disease Patients

✍ Zelinkova, Zuzana; van der Ent, Cokkie; Bruin, Karlien F.; van Baalen, Onno; Ver 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Foot drop developing during infliximab t

Foot drop developing during infliximab therapy for inflammatory bowel disease

✍ K. Subramaniam; A. Hughes; P. Pavli 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB

Infliximab Therapy in Children and Adole

Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease

✍ Gabor Veres, Dr Robert N. Baldassano, Petar Mamula 📂 Article 📅 2007 🏛 Springer International Publishing AG 🌐 English ⚖ 188 KB

Peripheral neuropathy with infliximab th

Peripheral neuropathy with infliximab therapy in inflammatory bowel disease

✍ D.C. Burger; T.H.J. Florin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB

Are accelerated infliximab infusions saf

Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?

✍ Shivaram Bhat; Divyesh Sharma; Pauline Doherty; Tony C.K. Tham; Grant R. Caddy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Background: Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). The manufacturerrecommended administration is over 2 hours followed by 2 hours of patient observation. The data relating to adverse outcomes in patients receiving accelerated infusions for IBD